Attached files

file filename
EX-99.1 - OCD DIVESTITURE PRESS RELEASE - JOHNSON & JOHNSONexhibit991-ocddivestiture.htm



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): June 30, 2014


 
(Exact name of registrant as specified in its charter)
 
 

New Jersey
I-3215
22-1024240
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)


One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933
 
(Address of Principal Executive Offices)  (Zip Code)
 
Registrant's telephone number, including area code: 732-524-0400
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 












 
Item 8.01. Other Events

On June 30, 2014, the Registrant announced that it has completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4 billion, subject to customary adjustments. Under the terms of the transaction, The Carlyle Group has acquired the Ortho-Clinical Diagnostics business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases. The Ortho-Clinical Diagnostics business generated net sales of approximately $1.9 billion in 2013.

The Registrant will discuss the financial impact of this divestiture during its scheduled quarterly earnings call on July 15, 2014.

The related press release dated June 30, 2014 is attached as Exhibit 99.1 to this Report.


Item 9.01    Financial Statements and Exhibits.
 
(d)    Exhibits.

Exhibit No.    Description

99.1        Press Release dated June 30, 2014



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
 
Johnson & Johnson
(Registrant)
 
June 30, 2014
 
By:
/s/ Lacey P. Elberg
 
 
 
 
Lacey P. Elberg
Assistant Secretary